Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Proposes Independent Contractor To Track User Fee Dollars Used To Pay FTEs

Executive Summary

The agency published minutes from three MDUFA V user fee meetings with medtech industry. The talks include conversations about carryover funds and filling FTEs from past user fee deals.

You may also be interested in...



FDA’s Shuren Grilled About Handling Of MDUFA V At House Hearing

Jeff Shuren, the director of the US agency’s device center, was quizzed by the House health subcommittee on why the new user-fee deal had reached Congress late and why there was an apparent lack of transparency around the negotiation process, among other issues. Shuren said part of the delay was due to the center and industry being “hammered by COVID.” 

FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal

The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.

Penumbra Class I Recall Again Raises Concerns About 510(k) Pathway, Device Creep

A case study of the Penumbra JET 7 class I recall in JAMA has again raised concerns about shortcomings in the US FDA’s 510(k) pathway in the medical community.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT144812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel